广谱唑类抗真菌新药艾沙康唑  

A New Broad-spectrum Triazole Antifungal Agent: Isavuconazole

作　　者：顾卫青 朱江 董先红 

机构地区：[1]上海市浦东新区祝桥社区卫生服务中心,上海201300 [2]浦东新区光明中医医院

出　　处：《中国药师》2016年第1期166-168,共3页China Pharmacist

摘　　要：侵袭性真菌感染是一种严重危及生命的真菌病,死亡率较高。艾沙康唑是一种广谱的用于治疗成人侵袭性曲霉菌病和毛霉菌病引起的严重感染的抗真菌药物,于2015年3月6日被美国FDA批准上市。本文综述艾沙康唑的作用机制、药动学、药效学、临床试验、不良反应及药物相互作用。Invasive fungal infection is a severe life-threatening fungal disease with high mortality. Isavuconazole is a new broad- spectrum antifungal agent approved by FDA on March 6, 2015, which is used to treat adults with serious infection such as invasive aspergillosis and invasive mucormycosis. The action mechanisms, pharmacokinetics, pharmacodynamics, clinical trials, adverse effects and drug interactions of isavuconazole were reviewed in the paper.

关 键 词：艾沙康唑 侵袭性真菌感染 药动学 临床试验 不良反应 

分 类 号：R978.5[医药卫生—药品]